Anthony J. Santella, Dr.P.H., explains why prevention efforts are lagging within the largest suburban HIV epidemic in the U.S.
However, a number of leading clinicians argue that the results should not deter care providers from prescribing PrEP for patients who are most at risk for HIV.
Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.
Although people living with HIV who "party and play" appear more likely to struggle with treatment adherence, new research suggests that concern does not apply to PrEP.
This study shows that with the right supportive services, black men who have sex with men will use pre-exposure prophylaxis (PrEP), and with very high adherence.
Some have expressed concern that, as PrEP use increases in the U.S., so will the transmission of other STIs. A new study pushes back against that worry.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.